Your browser is no longer supported. Please, upgrade your browser.
Settings
ABEO Abeona Therapeutics Inc. daily Stock Chart
ABEO [NASD]
Abeona Therapeutics Inc.
Index- P/E- EPS (ttm)-0.70 Insider Own34.94% Shs Outstand47.45M Perf Week2.80%
Market Cap785.30M Forward P/E- EPS next Y-0.73 Insider Trans0.00% Shs Float30.78M Perf Month3.28%
Income-30.50M PEG- EPS next Q-0.19 Inst Own69.70% Short Float41.32% Perf Quarter5.08%
Sales3.20M P/S245.41 EPS this Y-2.50% Inst Trans11.45% Short Ratio12.13 Perf Half Y8.88%
Book/sh3.60 P/B4.60 EPS next Y5.20% ROA-22.30% Target Price29.31 Perf Year237.76%
Cash/sh2.78 P/C5.95 EPS next 5Y- ROE-23.60% 52W Range4.75 - 22.75 Perf YTD4.42%
Dividend- P/FCF- EPS past 5Y52.10% ROI- 52W High-27.25% Beta1.18
Dividend %- Quick Ratio20.80 Sales past 5Y-28.30% Gross Margin- 52W Low248.42% ATR1.24
Employees42 Current Ratio20.80 Sales Q/Q1296.80% Oper. Margin- RSI (14)46.12 Volatility5.00% 6.86%
OptionableYes Debt/Eq0.00 EPS Q/Q-38.00% Profit Margin- Rel Volume0.91 Prev Close16.10
ShortableYes LT Debt/Eq0.00 EarningsJun 15 AMC Payout- Avg Volume1.05M Price16.55
Recom1.80 SMA20-0.05% SMA50-8.23% SMA2002.17% Volume958,276 Change2.80%
Jun-05-18Initiated Seaport Global Securities Buy $29
Nov-08-17Initiated SunTrust Buy $26
Oct-16-17Reiterated H.C. Wainwright Buy $20 → $30
Oct-11-17Reiterated Cantor Fitzgerald Overweight $21 → $34
Oct-10-17Initiated Citigroup Buy $32
Oct-05-17Reiterated Maxim Group Buy $17 → $35
Sep-15-17Initiated RBC Capital Mkts Outperform $23
Jul-18-17Reiterated Maxim Group Buy $14 → $17
Jun-22-17Resumed Jefferies Buy $22
Jan-06-17Initiated Jefferies Buy
Sep-29-16Reiterated Maxim Group Buy $8 → $14
Dec-16-15Initiated Maxim Group Buy $6
Jul-20-15Initiated MLV & Co Buy $15
Jun-18-18 04:21PM  Newman Ferrara LLP Announces Corporate Governance Investigation of Abeona Therapeutics Inc. ABEO Business Wire
Jun-07-18 07:47AM  57% Sales Growth, Top-Notch Partners At Overlooked Gene and Cell Therapy Issue ORGS ACCESSWIRE
Jun-06-18 08:45AM  Abeona Therapeutics Announces Upcoming Presentation at Jefferies 2018 Global Healthcare Conference GlobeNewswire
Jun-05-18 03:21PM  Abeona Therapeutics Has First-Mover Potential In Rare Diseases, Seaport Says In Bullish Initiation Benzinga +6.92%
07:20AM  Free Technical Research on Versartis and Three More Biotech Equities ACCESSWIRE
Jun-04-18 02:30PM  9 Stocks Poised for Healthy Long-Term Gains Investopedia -11.29%
May-31-18 08:45AM  Abeona Therapeutics Announces Opening of Commercial Gene & Cell Therapy Manufacturing Facility in Ohio GlobeNewswire -5.60%
08:30AM  Analysis: Positioning to Benefit within Avadel Pharmaceuticals, Abeona Therapeutics, BanColombia S.A, Aercap Holdings N.V, Kite Realty Group Trust, and Credicorp Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
May-18-18 05:30PM  Here's Why Abeona Therapeutics Stock Dropped 12% Today Motley Fool -12.00%
09:25AM  Abeona Therapeutics Provides Clinical Update on MPS IIIA Gene Therapy Trial at the 21st Annual ASGCT Meeting GlobeNewswire
May-17-18 09:20AM  Abeona Reports Update from EB-101 Gene Therapy in Epidermolysis Bullosa at 21st Annual ASGCT Meeting GlobeNewswire
May-15-18 06:02PM  Edited Transcript of ABEO earnings conference call or presentation 14-May-18 2:00pm GMT Thomson Reuters StreetEvents
May-14-18 12:19PM  Abeona Therapeutics Inc (NASDAQ:ABEO): Does The -41.52% Earnings Drop Reflect A Longer Term Trend? Simply Wall St. +6.36%
08:15AM  Abeona Therapeutics Announces Appointment of Stefano Buono and Richard Van Duyne to its Board of Directors GlobeNewswire
May-11-18 08:25AM  Abeona Therapeutics: 1Q Earnings Snapshot Associated Press
08:16AM  Abeona Therapeutics Reports First Quarter 2018 Financial Results and Business Highlights GlobeNewswire
May-08-18 08:15AM  Abeona Therapeutics Announces Upcoming Presentations GlobeNewswire
Apr-27-18 11:10AM  Kensho's genetic engineering index CNBC Videos
Apr-24-18 07:40AM  Wired News European Medicines Agency Granted Orphan Drug Designation for Abeonas ABO-202 Gene Therapy Program in Batten Disease ACCESSWIRE -7.75%
Apr-23-18 08:16AM  Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA GlobeNewswire
08:15AM  Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA GlobeNewswire
Apr-20-18 08:16AM  Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease GlobeNewswire
Apr-12-18 09:27PM  When Will Abeona Therapeutics Inc (NASDAQ:ABEO) Breakeven? Simply Wall St.
Apr-10-18 08:38AM  Why Abeona Therapeutics (ABEO) Could Be Positioned for a Slump Zacks +7.25%
08:30AM  Todays Research Reports on Trending Tickers: Abeona Therapeutics and Spark Therapeutics ACCESSWIRE
Apr-06-18 07:50AM  Report: Exploring Fundamental Drivers Behind Haverty Furniture Companies, Scholastic, Dover, MYR Group, Abeona Therapeutics, and U.S. Global Investors New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Apr-02-18 08:16AM  Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer GlobeNewswire
06:00AM  7 Stocks for the Biotech Takeover Wave Investopedia
Mar-27-18 07:21PM  Edited Transcript of ABEO earnings conference call or presentation 27-Mar-18 2:00pm GMT Thomson Reuters StreetEvents -6.98%
07:00AM  Abeona Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-20-18 02:58PM  15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies TheStreet.com
Mar-16-18 05:34PM  Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights GlobeNewswire
05:10PM  Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights GlobeNewswire
Mar-15-18 08:45AM  Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 Disease GlobeNewswire
Feb-22-18 07:35AM  New Research Coverage Highlights Western Alliance, Matson, Vail Resorts, Abeona Therapeutics, Under Armour, and AGNC Investment Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire +14.10%
Feb-21-18 08:45AM  Abeona Therapeutics Announces Upcoming Conference Participation GlobeNewswire
Feb-12-18 08:45AM  Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-202 Gene Therapy Program in Infantile Batten Disease GlobeNewswire -10.48%
Feb-08-18 02:00PM  Abeona Therapeutics Reports Top-Line Data from Phase 1/2 Gene Therapy Trial in MPS IIIA GlobeNewswire -14.56%
Feb-07-18 07:01PM  Why Abeona Therapeutics Jumped 14% on Wednesday Motley Fool +14.11%
04:42PM  Traders Need to Adapt to a New Reality TheStreet.com
08:46AM  Abeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical Trial GlobeNewswire
08:45AM  Abeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical Trial GlobeNewswire
Feb-02-18 08:54AM  Abeona Therapeutics Announces Upcoming Presentations at the 14th Annual WORLDSymposium GlobeNewswire
08:46AM  Abeona Therapeutics Announces Upcoming Presentations at the 14th Annual WORLDSymposium GlobeNewswire
Jan-29-18 09:45AM  UPDATE: Abeona shares rise 10% on 'regenerative medicine advanced therapy' designation from FDA MarketWatch
08:46AM  Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis Bullosa GlobeNewswire
08:45AM  Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis Bullosa GlobeNewswire
Jan-02-18 10:35AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Abeona Therapeutics Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire +8.52%
Dec-28-17 11:44AM  ETFs with exposure to Abeona Therapeutics, Inc. : December 28, 2017 Capital Cube
Dec-27-17 08:56AM  Abeona Therapeutics, Inc. :ABEO-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017 Capital Cube
Dec-20-17 08:46AM  Abeona Therapeutics Enrolls First Patient in ABO-101 Phase 1/2 Clinical Trial for MPS IIIB GlobeNewswire
08:45AM  Abeona Therapeutics Enrolls First Patient in ABO-101 Phase 1/2 Clinical Trial for MPS IIIB GlobeNewswire
Dec-19-17 01:37PM  7 Stocks Ready to Jump Another 30% in 2018 InvestorPlace
Nov-29-17 08:10AM  Edited Transcript of ABEO earnings conference call or presentation 20-Nov-17 3:00pm GMT Thomson Reuters StreetEvents
Nov-27-17 07:31AM  Abeona Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ABEO-US : November 27, 2017 Capital Cube
Nov-22-17 07:20AM  Featured Company News - Celldex Starts Phase-2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous Cell Carcinoma ACCESSWIRE
Nov-17-17 01:33PM  Abeona Therapeutics, Inc. Value Analysis (NASDAQ:ABEO) : November 17, 2017 Capital Cube
Nov-16-17 07:05AM  Abeona Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ABEO-US : November 16, 2017 Capital Cube
Nov-15-17 08:31AM  Abeona Therapeutics reports 3Q loss Associated Press +10.93%
08:26AM  Abeona Reports Third Quarter 2017 Financial Results and Recent Business Highlights GlobeNewswire
08:25AM  Abeona Reports Third Quarter 2017 Financial Results and Recent Business Highlights GlobeNewswire
Nov-13-17 08:45AM  Abeona Management to Present at Multiple Conferences in November GlobeNewswire
Nov-09-17 08:46AM  Abeona Enrolls First Subject in Spain in Ongoing Phase 1/2 Clinical Trial in MPS IIIA GlobeNewswire
08:45AM  Abeona Enrolls First Subject in Spain in Ongoing Phase 1/2 Clinical Trial in MPS IIIA GlobeNewswire
Oct-20-17 01:19PM  Market Still Lacks Ability to Find Volatility TheStreet.com +7.04%
Oct-19-17 09:39AM  Abeona Announces Closing of $92 Million Underwritten Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Oct-17-17 09:24AM  Abeona Shares Higher After Pricing Stock Offering -- Biotech Movers TheStreet.com +7.19%
Oct-16-17 09:45PM  Abeona Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire
04:01PM  Abeona Therapeutics Announces Public Offering of Common Stock GlobeNewswire
08:27AM  Abeona Announces $13.85M Grant from Leading Sanfilippo Syndrome Foundations for Clinical Development of MPS III Gene Therapies GlobeNewswire
Oct-11-17 12:11PM  Here's Why Abeona Therapeutics Inc. Stock Spiked Today Motley Fool
08:53AM  Are Options Traders Betting on a Big Move in Abeona Therapeutics (ABEO) Stock? Zacks
08:19AM  Abeona Therapeutics Enrolls First Two Patients in Pivotal Expansion of Phase 1/2 Clinical Trial in MPS IIIA GlobeNewswire
Oct-10-17 04:20PM  Edited Transcript of ABEO earnings conference call or presentation 22-Aug-17 2:00pm GMT Thomson Reuters StreetEvents +14.00%
Oct-06-17 08:25AM  Abeona Announces Top-Line One Year Data from ABO-102 MPS IIIA Trial at ARMs Cell & Gene Meeting on the Mesa GlobeNewswire
Oct-04-17 08:53AM  Abeona Therapeutics Announces Dedication of Commercial Gene Therapy Manufacturing Facility in Cleveland, Ohio GlobeNewswire
Oct-03-17 01:22PM  Andreas Halvorsen Scoops Up Abeona Therapeutics GuruFocus.com
Sep-28-17 08:32AM  Abeona Therapeutics and Brammer Bio Announce Collaboration for Commercial Translation of ABO-102 GlobeNewswire +11.88%
Sep-27-17 05:59PM  "Fast Money" final trades: XOM, C and more CNBC Videos +7.07%
Sep-22-17 08:45AM  Abeona Therapeutics Announces Upcoming Conference Participation GlobeNewswire -7.72%
Sep-21-17 02:58PM  4 Sell-Ranked Biotech Stocks with Falling Estimates to Avoid Zacks
Sep-20-17 11:17AM  Here's Why These 3 Biotech Stocks Might Stop Rallying Zacks
Sep-18-17 05:16PM  ETFs with exposure to Abeona Therapeutics, Inc. : September 18, 2017 Capital Cube
02:16PM  RBC Capital's Marc Harris breaks down his best biotech pi... CNBC Videos
08:35AM  Abeona Therapeutics (ABEO) Surges: Stock Moves 22.9% Higher Zacks
Sep-15-17 12:13PM  How Should You Think About Abeona Therapeutics Incs (ABEO) Risks? Simply Wall St. +22.86%
Aug-31-17 05:00PM  ETFs with exposure to Abeona Therapeutics, Inc. : August 31, 2017 Capital Cube
04:01PM  Biotechs On The Move Forbes
Aug-29-17 09:05AM  Abeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy in Epidermolysis Bullosa GlobeNewswire +18.42%
Aug-25-17 07:30AM  Corporate News Blog - BioDelivery Sciences CEO Dr. Mark A. Sirgo to Retire at Year-End; Will Continue as Vice Chairman ACCESSWIRE -5.73%
Aug-24-17 11:10AM  Abeona Therapeutics, Inc. :ABEO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube +9.71%
Aug-17-17 09:15AM  Abeona Therapeutics to Host Gene Therapy R&D Day on October 11, 2017 GlobeNewswire
Aug-16-17 09:39AM  Abeona Therapeutics Announces Pivotal Expansion of ABO-102 Gene Therapy Clinical Trials in Sanfilippo Syndrome Type A GlobeNewswire
Aug-15-17 11:22PM  Abeona Therapeutics reports 2Q loss Associated Press +9.46%
08:25AM  Abeona Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights GlobeNewswire
Jul-25-17 08:05AM  Abeona Therapeutics Announces Appointment of Juan Ruiz as Chief Medical Officer GlobeNewswire
Jul-21-17 01:44PM  Abeona Therapeutics reports 4Q loss Associated Press
Jul-18-17 08:05AM  Abeona Therapeutics Receives Guidance from FDA to Commence Pivotal Phase 3 for EB-101 Gene Therapy for Patients with Epidermolysis Bullosa GlobeNewswire
Jul-10-17 01:49PM  ETFs with exposure to Abeona Therapeutics, Inc. : July 10, 2017 Capital Cube +10.18%
Jul-07-17 05:25PM  Ahead of this year's MLB All-Star Game, here are 4 home r... CNBC Videos +5.70%
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.